ATE320419T1 - Indazolderivate mit 5-ht2-rezeptor-aktivität - Google Patents

Indazolderivate mit 5-ht2-rezeptor-aktivität

Info

Publication number
ATE320419T1
ATE320419T1 AT99943082T AT99943082T ATE320419T1 AT E320419 T1 ATE320419 T1 AT E320419T1 AT 99943082 T AT99943082 T AT 99943082T AT 99943082 T AT99943082 T AT 99943082T AT E320419 T1 ATE320419 T1 AT E320419T1
Authority
AT
Austria
Prior art keywords
alkyl
disorders
alkoxy
hydrogen
treatment
Prior art date
Application number
AT99943082T
Other languages
German (de)
English (en)
Inventor
David Reginald Adams
Jonathan Mark Bentley
Jonathan Richard Anthon Roffey
Richard John Hamlyn
Ashley Roger George
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Application granted granted Critical
Publication of ATE320419T1 publication Critical patent/ATE320419T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT99943082T 1998-09-01 1999-09-01 Indazolderivate mit 5-ht2-rezeptor-aktivität ATE320419T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819032.5A GB9819032D0 (en) 1998-09-01 1998-09-01 Chemical compounds IV

Publications (1)

Publication Number Publication Date
ATE320419T1 true ATE320419T1 (de) 2006-04-15

Family

ID=10838164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99943082T ATE320419T1 (de) 1998-09-01 1999-09-01 Indazolderivate mit 5-ht2-rezeptor-aktivität

Country Status (10)

Country Link
US (1) US6552062B1 (cg-RX-API-DMAC7.html)
EP (1) EP1129078B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002525280A (cg-RX-API-DMAC7.html)
AT (1) ATE320419T1 (cg-RX-API-DMAC7.html)
AU (1) AU5636799A (cg-RX-API-DMAC7.html)
CA (1) CA2341612A1 (cg-RX-API-DMAC7.html)
DE (1) DE69930397T2 (cg-RX-API-DMAC7.html)
ES (1) ES2260931T3 (cg-RX-API-DMAC7.html)
GB (1) GB9819032D0 (cg-RX-API-DMAC7.html)
WO (1) WO2000012481A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820767D0 (en) * 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
PL358481A1 (en) * 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
NZ525699A (en) 2000-11-20 2005-03-24 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
US6780862B2 (en) 2000-12-20 2004-08-24 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
WO2003057213A2 (en) * 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
NZ536664A (en) 2002-06-19 2007-07-27 Biovitrum Ab Piperazinylpyrazine derivative compounds, their use and preparation
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
WO2006022420A1 (ja) 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0232059A (ja) * 1988-07-18 1990-02-01 Kyowa Hakko Kogyo Co Ltd インダゾール誘導体
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
TW270114B (cg-RX-API-DMAC7.html) * 1993-10-22 1996-02-11 Hoffmann La Roche
JPH08225535A (ja) * 1994-11-15 1996-09-03 Dai Ichi Seiyaku Co Ltd インダゾール誘導体
AU5343298A (en) * 1997-01-13 1998-08-03 Yamanouchi Pharmaceutical Co., Ltd. 5-ht2c receptor agonists and aminoalkylindazole derivatives

Also Published As

Publication number Publication date
WO2000012481A3 (en) 2000-06-08
JP2002525280A (ja) 2002-08-13
CA2341612A1 (en) 2000-03-09
US6552062B1 (en) 2003-04-22
ES2260931T3 (es) 2006-11-01
DE69930397D1 (de) 2006-05-11
EP1129078B1 (en) 2006-03-15
DE69930397T2 (de) 2006-11-30
GB9819032D0 (en) 1998-10-28
WO2000012481A2 (en) 2000-03-09
EP1129078A2 (en) 2001-09-05
AU5636799A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
ZA200101457B (en) Pyrroloindoles, pyridoindoles and azepinoindoles as 5-HT2C agonists.
ATE320419T1 (de) Indazolderivate mit 5-ht2-rezeptor-aktivität
PT1109809E (pt) Pirroloquinolinas para tratamento da obesidade
WO2000012482A3 (en) Indazole derivatives with 5-ht2 receptor activity
WO2000017170A3 (en) N1-substituted benzopyrazoles as inhibitors of 5-ht2 receptors
ATE239731T1 (de) Pyrazino(aza)indolderivate
AR029815A1 (es) Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento
HUP0301201A2 (hu) Kinazolinonok és kinazolinonokat tartalmazó készítmények
BR0013307A (pt) Compostos quìmicos de indol, seus usos e métodos de preparação, método de tratamento, composição e método de fabricação de uma composição farmacêutica que os contêm
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
WO2003033472A1 (en) Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
IL158269A0 (en) Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
GB0018272D0 (en) Chemical compounds IV
NZ512981A (en) Use of pyridazino[4,5-b]indole-1-acetamide derivatives for treating diseases related to the dysfunction of peripheral benzodiazepine receptors
AU2116900A (en) 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
NZ337048A (en) Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer
AR029353A1 (es) Un compuesto derivado de pirazinoindol, uso del mismo, una composicion farmaceutica que lo comprende y un metodo para la fabricacion de dicha composicion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties